Cognizant upgraded to Buy from Neutral at UBS UBS upgraded Cognizant and said it is well positioned for the current demand environment as IT budgets are focused on cost optimization and believes discretionary project spending will be solid. The analyst expect Cognizant to announce a more formal capital return policy this year and views valuation as attractive. Price target raised to $58 from $50.
News For CTSH From The Last 14 Days
Check below for free stories on CTSH the last two weeks.
Cognizant deal with Health Net has encouraging read through, says Cowen Cowen noted Cognizant (CTSH) shareholders were concerned over its deal with Health Net (HNT) but noted management feels the deal is a true partnership. The firm feels management's positive comments are encouraging and address the execution and profitability concerns of shareholders. Shares of Cognizant are Outperform rated with a $50 price target.
Health Net fundamentals remain favorable, says Susquehanna Susquehanna said Health Net (HNT) fundamentals remain favorable following meetings with management. The firm cited the company's conservative outlook and the benefit of its back office contract with Cognizant (CTSH) which positions the company well for sustainable earnings growth through 2016. Shares of Health Net remain Positive rated with a $55 price target on the shares.